Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology

Open Access 20-04-2024 | Peritoneal Dialysis | Original article

Circulating galectin-3 level association with cardiovascular risk factors during peritoneal dialysis

Authors: Xuerui Yang, Jun Yang, Youjia Zeng, Ling Peng, Xingzheng Liu, Jinying Mo, Taifen Wang, Yutong Yao, Yihou Zheng, Gaofeng Song

Published in: Clinical and Experimental Nephrology

Login to get access

Abstract

Objective

Cardiovascular disease (CVD) represents the primary cause of mortality in patients afflicted with end-stage renal disease and undergoing peritoneal dialysis (PD) treatment. Galectin-3 (Gal-3), a molecule known to exhibit a correlation with CVD mortality garners considerable interest. The objective of this study was to explore the potential association between serum Gal-3 levels and other CVD risk factors among PD patients.

Methods

In this cross-sectional study, a total of 114 PD patients with a minimum of 3 months of PD treatment were enrolled. Serum Gal-3 levels were quantified using an enzyme-linked immunosorbent assay. The data of patients with Gal-3 levels higher and lower than 26.744 pg/ml were compared using Mann–Whitney U tests or t tests. Pearson’s correlation or Spearman’s correlation analysis and multivariate regression were used to assess the associations between the known risk factors for CVD and Gal-3.

Results

In comparison to the inter-group baseline data, the low Gal-3 group exhibited a higher glomerular filtration rate (GFR). Gal-3 levels correlate positively with PD duration, B-type natriuretic peptide (BNP), growth differentiation factor 15 (GDF-15), interventricular septal thickness in diastolic (IVST), and left ventricular mass index (LVMI). Conversely, Gal-3 exhibited a negative correlation with albumin levels. Multivariate linear regression analysis demonstrated a positive correlation between Gal-3 levels and BNP, GDF-15, PD duration, IVST and LVMI. Gal-3 levels were negatively correlated with albumin levels.

Conclusions

Gal-3 was strongly associated with BNP, GDF-15, IVST and LVMI in patients undergoing PD treatment. Prospective studies should be carried out to determine whether Gal-3 can be a promising biomarker in predicting increased risk of adverse cardiovascular events in PD patients.
Literature
1.
Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, Wiecek A, Zoccali C, London GM. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet. 2014;383(9931):1831–43.CrossRefPubMed
2.
Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, Jha V, Makusidi MA, McCulloch M, Shah N, Wainstein M, Johnson DW. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022;18(12):779–93.CrossRefPubMedPubMedCentral
3.
Rossignol P, Pitt B, Thompson A, Zannad F. Roadmap for cardiovascular prevention trials in chronic kidney disease. Lancet. 2016;388(10055):1964–6.CrossRefPubMed
4.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW, American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–65.CrossRefPubMed
5.
Hara A, Niwa M, Kanayama T, Noguchi K, Niwa A, Matsuo M, Kuroda T, Hatano Y, Okada H, Tomita H. Galectin-3: a potential prognostic and diagnostic marker for heart disease and detection of early stage pathology. Biomolecules. 2020;10(9):1277.CrossRefPubMedPubMedCentral
6.
Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8.CrossRefPubMed
7.
Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, Klein AL. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385–90.CrossRefPubMedPubMedCentral
8.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.CrossRefPubMed
9.
Liu S, Wu Q, Zhang S, Wang Z, Liu H, Teng L, Xiao P, Lu Y, Wang X, Dong C, Xiao J, Zhang J. Serum Galectin-3 levels and all-cause and cardiovascular mortality in maintenance hemodialysis patients: a prospective cohort study. BMC Nephrol. 2022;23(1):5.CrossRefPubMedPubMedCentral
10.
Einbinder Y, Siboni A, Zaidenstein S, Cohen-Hagai K, Benchetrit S, Zitman-Gal T. Presence of galectin-3 in peritoneal dialysate. Does it have a role in the peritoneal membrane inflammatory process? Nephrology (Carlton). 2022;27(1):104–8.CrossRefPubMed
11.
12.
Rebholz CM, Selvin E, Liang M, Ballantyne CM, Hoogeveen RC, Aguilar D, McEvoy JW, Grams ME, Coresh J. Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease. Kidney Int. 2018;93(1):252–9.CrossRefPubMed
13.
Lin YH, Chou CH, Wu XM, Chang YY, Hung CS, Chen YH, Tzeng YL, Wu VC, Ho YL, Hsieh FJ, Wu KD. Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One. 2014;2(9):e95254.CrossRef
14.
Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008;172(2):288–98.CrossRefPubMedPubMedCentral
15.
16.
Kim AJ, Ro H, Kim H, Ko KP, Chang JH, Lee HH, Chung W, Jung JY. Elevated levels of soluble ST2 but not galectin-3 are associated with increased risk of mortality in hemodialysis patients. Kidney Res Clin Pract. 2021;40(1):109–19.CrossRefPubMedPubMedCentral
17.
Branco P, Calça R, Martins AR, Mateus C, Jervis MJ, Gomes DP, Azeredo-Lopes S, De Melo Junior AF, Sousa C, Civantos E, Mas-Fontao S, Gaspar A, Ramos S, Morello J, Nolasco F, Rodrigues A, Pereira SA. Fibrosis of peritoneal membrane, molecular indicators of aging and frailty unveil vulnerable patients in long- term peritoneal dialysis. Int J Mol Sci. 2023;24(5):5020.CrossRefPubMedPubMedCentral
18.
Masola V, Bonomini M, Borrelli S, Di Liberato L, Vecchi L, Onisto M, Gambaro G, Palumbo R, Arduini A. Fibrosis of peritoneal membrane as target of new therapies in peritoneal dialysis. Int J Mol Sci. 2022;23(9):4831.CrossRefPubMedPubMedCentral
19.
Ou SM, Tsai MT, Chen HY, Li FA, Tseng WC, Lee KH, Chang FP, Lin YP, Yang RB, Tarng DC. Identification of galectin-3 as potential biomarkers for renal fibrosis by RNA-sequencing and clinicopathologic findings of kidney biopsy. Front Med (Lausanne). 2021;12(8):748225.CrossRef
20.
Tsai MT, Ou SM, Chen HY, Tseng WC, Lee KH, Yang CY, Yang RB, Tarng DC. Relationship between circulating galectin-3, systemic inflammation, and protein- energy wasting in chronic hemodialysis patients. Nutrients. 2021;13(8):2803.CrossRefPubMedPubMedCentral
21.
Siddiqui JA, Pothuraju R, Khan P, Sharma G, Muniyan S, Seshacharyulu P, Jain M, Nasser MW, Batra SK. Pathophysiological role of growth differentiation factor 15 (GDF15) in obesity, cancer, and cachexia. Cytokine Growth Factor Rev. 2022;64:71–83.CrossRefPubMed
22.
Zhou Z, Liu H, Ju H, Chen H, Jin H, Sun M. Circulating GDF-15 in relation to the progression and prognosis of chronic kidney disease: a systematic review and dose-response meta-analysis. Eur J Intern Med. 2023;110:77–85.CrossRefPubMed
23.
24.
Nopp S, Königsbrügge O, Schmaldienst S, Klauser-Braun R, Lorenz M, Pabinger I, Säemann M, Ay C. Growth differentiation factor-15 predicts major bleeding, major adverse cardiac events and mortality in patients with end-stage kidney disease on haemodialysis: findings from the VIVALDI study. Nephrol Dial Transplant. 2023;38(8):1836–47.CrossRefPubMed
25.
Wang AY, Lam CW, Yu CM, Wang M, Chan IH, Zhang Y, Lui SF, Sanderson JE. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol. 2007;18(1):321–30.CrossRefPubMed
26.
Volpe M, Carnovali M, Mastromarino V. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond). 2016;130(2):57–77.CrossRefPubMed
27.
Chang P, Zhang X, Zhang J, Wang J, Wang X, Li M, Wang R, Yu J, Fu F. BNP protects against diabetic cardiomyopathy by promoting Opa1-mediated mitochondrial fusion via activating the PKG-STAT3 pathway. Redox Biol. 2023;62:102702.CrossRefPubMedPubMedCentral
28.
Rutten JHW, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, Boomsma F, van den Meiracker AH, NECOSAD Study Group. B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. Perit Dial Int. 2006;26:598–608.CrossRefPubMed
29.
Haapio M, Honkanen E, Ronco C. Brain natriuretic peptide in peritoneal dialysis patients. Contrib Nephrol. 2009;163:110–6.CrossRefPubMed
30.
Fermann GJ, Lindsell CJ, Storrow AB, Hart K, Sperling M, Roll S, Weintraub NL, Miller KF, Maron DJ, Naftilan AJ, McPherson JA, Sawyer DB, Christenson R, Collins SP. Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers. 2012;17(8):706–13.CrossRefPubMedPubMedCentral
31.
Zhang T, Shao B, Liu GA. Research on clinical value of galectin-3 in evaluating the prognosis of acute heart failure. Eur Rev Med Pharmacol Sci. 2017;21(19):4406–10.PubMed
32.
Motiwala SR, Szymonifka J, Belcher A, Weiner RB, Baggish AL, Sluss P, Gaggin HK, Bhardwaj A, Januzzi JL. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013;15(10):1157–63.CrossRefPubMed
Metadata
Title
Circulating galectin-3 level association with cardiovascular risk factors during peritoneal dialysis
Authors
Xuerui Yang
Jun Yang
Youjia Zeng
Ling Peng
Xingzheng Liu
Jinying Mo
Taifen Wang
Yutong Yao
Yihou Zheng
Gaofeng Song
Publication date
20-04-2024
Publisher
Springer Nature Singapore
Published in
Clinical and Experimental Nephrology
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-024-02498-3
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits